Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.51 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.51 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29613178 | 1.00 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5744947 | 0.94 | RAB9A (0.52) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27924713 | 0.86 | L3MBTL1 (0.60) | RAB9AMEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL707407 | 0.85 | CA12 (0.67) | CA12CA1CA2CA7CA9 | |
| SCHEMBL29784637 | 0.83 | CYP11B1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL14493579 | 0.83 | CA12 (0.56) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1519827 | 0.83 | CYP11B1 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL9979785 | 0.82 | CA12 (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL5487018 | 0.81 | CYP11B2 (0.74) | MEN1KMT2ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL4684202 | 0.81 | F2 (0.47) | IMPDH2HDAC3HDAC1HDAC2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562017-A1 | NOVEL ACC INHIBITORS | Pfizer Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| CN-120019059-A | Novel ACC inhibitors | 辉瑞公司 | 2025-05-16 | — | — | CN | disclosed |
| US-20240109915-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-04-04 | — | — | US | disclosed |
| WO-2024023727-A1 | NOVEL ACC INHIBITORS | PFIZER INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| CN-109071447-B | Tetracyclic pyridinone compounds as antiviral agents | 诺华股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-107820496-B | Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infections | 豪夫迈·罗氏有限公司 | 2020-11-03 | — | — | CN | disclosed |
| CN-107820496-A | For treating and preventing the hepatitis b virus infected new formic acid derivates of 4 oxo pyridine of Fourth Ring 3 | 豪夫迈·罗氏有限公司 | 2018-03-20 | — | — | CN | disclosed |
| US-20060079533-A1 | Methods of treating alzheimer's disease | NIEMAN JAMES A | 2006-04-13 | — | — | US | disclosed |
| WO-2002076440-A2 | METHODS OF TREATING ALZHEIMER'S DISEASE WITH PIPERIDIN DERIVATES | ELAN PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| US-6150526-A | Piperidine derivative having renin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 2000-11-21 | — | — | US | disclosed |
| US-6051712-A | PREVENTION OF HIGH BLOOD PRESSURE AND CARDIAC INSUFFICIENCY, AS WELL AS GLAUCOMA, CARDIAC INFARCT, KIDNEY INSUFFICIENCY AND RESTENOSIS | HOFFMANN-LA ROCHE INC. (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109915-A1 | NOVEL ACC INHIBITORS | CBR3, NAT1, ACACB | CA12 1526/4885CA1 765/4885CA2 269/4885 |
| US-20060079533-A1 | Methods of treating alzheimer's disease | BACE1, PSEN1, PSEN2 | CA12 2820/4885CA1 124/4885CA2 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.